XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3Close
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash provided by (used for) operating activities    
Net income (loss) $ 1,284 $ 1,088
Depreciation and amortization 921 883
Deferred and prepaid income taxes 10 (74)
Stock-based compensation expense 197 174
Goodwill and other intangible asset impairment charges 276 58
Net loss (gain) on investments and notes receivable 60 48
Contingent consideration net expense (benefit) (4) 43
Inventory step-up amortization 0 6
Other, net 22 33
Trade accounts receivable (261) (164)
Inventories (274) (601)
Other assets (109) (43)
Accounts payable, accrued expenses and other liabilities (142) 95
Cash provided by (used for) operating activities 1,979 1,546 Close
Investing activities:    
Purchases of property, plant and equipment and internal use software (513) (444)
Proceeds from sale of property, plant and equipment 1 4
Payments for acquisitions of businesses, net of cash acquired (1,222) (1,018)
Payments for investments and acquisitions of certain technologies, net of investment proceeds (264) (89)
Proceeds from royalty rights 16 23
Proceeds from settlements of hedge contracts 0 2
Cash provided by (used for) investing activities (1,983) (1,521) Close
Financing activities:    
Payment of contingent consideration previously established in purchase accounting (131) (39)
Payments for royalty rights (26) (50)
Payments for finance leases (25) 0
Payments on short-term borrowings (504) 0
Proceeds from short-term borrowings, net of debt issuance costs 22 0
Net increase (decrease) in commercial paper 0 (4)
Proceeds from long-term borrowings, net of debt issuance costs 2,145 0
Cash dividends paid on preferred stock 0 (28)
Cash used to net share settle employee equity awards (83) (54)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans 202 165
Cash provided by (used for) financing activities 1,600 (10) Close
Effect of foreign exchange rates on cash (2) (8) Close
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents 1,594 7 Close
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 1,055 1,126
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period 2,649 1,132
Supplemental Information    
Stock-based compensation expense 197 174
Fair value of contingent consideration recorded in purchase accounting 29 0
Non-cash impact of transferred royalty rights (16) (23)
Cash and cash equivalents 2,502 952
Restricted cash and restricted cash equivalents included in Other current assets 70 123
Restricted cash equivalents included in Other long-term assets 78 58
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period $ 2,649 $ 1,132